Disease · MONDO_0004627

duodenitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. duodenitis. Diseases, record MONDO_0004627. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004627

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: duodenitis; Open Targets
Open Targets ID: MONDO_0004627; Open Targets
Other names: duodenum inflammation, inflammation of duodenum; Open Targets
Disease Ontology: DOID:8643; Disease Ontology
MeSH: D004382; MeSH
NCI Thesaurus: C94409; NCI Thesaurus
Highest stage of its drugs: Phase 3, for its one drug, from ClinicalTrials.gov; Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here
LIRENTELIMAB	CHEMBL4297878	Antibody	Phase 3	ClinicalTrials.gov	5	5	5

Source Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
SIGLEC8	Sialic acid-binding Ig-like lectin 8	1	Sialic acid-binding Ig-like lectin 8 inhibitor	Phase 3	https://conductscience.org/library/genes/27181

Source Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04322604	A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)	Phase 3	181	2024-01-02	Eosinophilic Gastritis, Eosinophilic Duodenitis	LIRENTELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04620811	An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)	Phase 3	159	2024-04-18	Eosinophilic Gastritis, Eosinophilic Duodenitis	LIRENTELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04856891	A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis	Phase 3	94	2024-01-02	Eosinophilic Duodenitis, Eosinophilic Gastroenteritis	LIRENTELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03664960	An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis	Phase 2	58	2024-02-28	Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis	LIRENTELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05152563	A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis	Phase 3	0		Eosinophilic Gastritis, Eosinophilic Duodenitis	LIRENTELIMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Achieving Mean Eosinophil Count ≤1 Cell/Hpf in 5 Highest Gastric Hpf and/or Mean Eosinophil Count ≤1 Cell/Hpf in 3 Highest Duodenal Hpf at Week 24	75 of 91	1 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: Proportion of Tissue Eosinophil Responders at Week 24	77 of 91	4 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: Number of Treatment Responders	39 of 91	3 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achieve ≥70% Reduction in TSS From Baseline to Weeks 23-24	26 of 91	18 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: deaths from any cause	0 of 91	0 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achieve ≥50% Reduction in TSS From Baseline to Weeks 23-24	36 of 91	29 of 89	180	NCT04322604	Trial comparisons
3 mg/kg of Lirentelimab (AK002) vs Placebo: serious adverse events	7 of 91	5 of 89	180	NCT04322604	Trial comparisons
Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): deaths from any cause	1 of 84	0 of 75	159	NCT04620811	Trial comparisons
Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): serious adverse events	14 of 84	6 of 75	159	NCT04620811	Trial comparisons
Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): Proportion of Tissue Eosinophil Responders	48 of 52	52 of 54	106	NCT04620811	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004627

GET https://conductscience.org/api/diseases/v1/MONDO_0004627/drugs

API reference For AI assistants